Donepezil Hydrochloride
FDA-approved product (tablet, oral), marketed as Adlarity, Aricept, Aricept Odt and 1 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Alzheimer disease
- Dementia
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Anticholinesterases
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA44.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli43.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae22.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis61.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Donepezil Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Pitavastatin SodiumExisting use: Abnormal circulating lipid concentration, Cardiovascular disease, Familial hypercholesterolemia and 2 more66.8% AI-predicted activityagainst M. tuberculosis18 registered studies
- AmisulprideExisting use: Nausea and vomiting, Post operative nausea and vomiting, Psychosis66.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- ItraconazoleExisting use: Aspergillosis, Blastomycosis, Candidiasis and 4 more66.7% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Dantrolene SodiumExisting use: Cerebral palsy, Fever, Malignant hyperthermia and 4 more66.6% AI-predicted activityagainst M. tuberculosis12 registered studies
- LurbinectedinExisting use: Cancer, Neoplasm, Small cell lung carcinoma66.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Methixene HydrochlorideExisting use: Parkinson disease66.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- Cisapride MonohydrateExisting use: Gastrointestinal disease66.5% AI-predicted activityagainst M. tuberculosis5 registered studies
- Angiotensin Ii AcetateExisting use: Cardiovascular disease, Hypotension, Septic shock and 1 more66.3% AI-predicted activityagainst M. tuberculosis10 registered studies
- QuazepamExisting use: Insomnia66.3% AI-predicted activityagainst M. tuberculosis1 registered study
- AbemaciclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more66.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TerconazoleExisting use: Triazole derivatives66.2% AI-predicted activityagainst M. tuberculosis10 registered studies
- Degarelix AcetateExisting use: Prostate adenocarcinoma, Prostate cancer, Prostate carcinoma66.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties
NCT00315367 · start 2004-09
Registered record
- Registry ID
- NCT00315367
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Donepezil HCI (drug)
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2004-09
- Completion
- 2007-10
- Enrolment
- 26
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRelapsing-Remitting Multiple SclerosisInterventionDonepezil HCI (drug)PhasePhase 4Registry statusCompletedAn Evaluation Of The Efficacy And Safety Of Donepezil Hydrochloride (E2020) In Migraine Prophylaxis
NCT01146509 · start 2003-01
Registered record
- Registry ID
- NCT01146509
- Conditions
- Migraine Headache
- Interventions
- Aricept (donepezil hydrochloride)
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2003-01
- Completion
- 2007-03
- Enrolment
- 89
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMigraine HeadacheInterventionAricept (donepezil hydrochloride)PhasePhase 2Registry statusCompletedThe CAMPUS Project: Cholinergic Augmentation of Cognitive Deficits in Schizophrenia
NCT00206947 · start 2002-12
Registered record
- Registry ID
- NCT00206947
- Conditions
- Schizophrenia
- Interventions
- donepezil (5-10 mg/day); Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2002-12
- Completion
- 2005-01
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophreniaInterventiondonepezil (5-10 mg/day); PlaceboPhasePhase 2Registry statusTerminatedDonepezil to Treat Dementia in Parkinson's Disease
NCT00030979 · start 2002-02
Registered record
- Registry ID
- NCT00030979
- Conditions
- Parkinson Disease
- Interventions
- Donepezil
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2002-02
- Completion
- 2005-03
- Enrolment
- 28
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionParkinson DiseaseInterventionDonepezilPhasePhase 4Registry statusCompletedTiagabine, Sertraline, or Donepezil for the Treatment of Cocaine Dependence - 9
NCT00015132 · start 1999-03
Registered record
- Registry ID
- NCT00015132
- Conditions
- Cocaine-Related Disorders
- Interventions
- Sertraline
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 1999-03
- Completion
- 2000-11
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCocaine-Related DisordersInterventionSertralinePhasePhase 2Registry statusCompleted